NEW BRUNSWICK, N.J., July 20 /PRNewswire/ -- The organizers of the 11th Annual Drug Delivery Technologies & Deal-Making Summit, to take place in New Brunswick New Jersey from September 25-27, are pleased to present the executive keynote panels that will take place during the morning general sessions on September 26 and 27. The panels are focused on the most pressing commercial considerations the industry faces and comprise speakers from the pharmaceutical, drug delivery, specialty pharmaceutical, and investment communities, reports Strategic Research Institute.
The annual conference is industry-focused and has attracted on average 300 executive attendees from around the world since its inception in 1995.
The 2006 Keynotes are the following:
New Partnerships and Investment in Drug Delivery and Specialty Pharmaceutical Companies
* Phyllis Gardner, M.D., Associate Professor of Medicine, Stanford University School of Medicine * Todd Brady, Principal, Domain Associates * Arthur Klausner, Partner, Pappas Ventures * Bill Slattery, Partner, Deerfield Management * Alex Zisson, Venture Partner, Thomas, McNerney & Partners Pharma’s View on Drug Delivery * Ralph Vitaro, Publisher/President, Drug Delivery Technology * Mandana Asgharnejad, Ph.D., Director, Scientific Liaison - External Scientific Affairs, Merck & Co., Inc. * Frank Grams, Global Head Drug Delivery Partnering, Roche * Keith R. Horspool, Ph.D., Assistant Director, Pharmaceutical R & D, Pfizer, Inc. * Ian McKenna, Alliance Management for Early-Stage Technologies and Biotechnology, Eli Lilly & Company * Matthew D. Roe, Senior Director, Business Development and Licensing, Genzyme Pharmaceuticals * Ronald L. Smith, Ph.D., Executive Director, Biopharmaceutics R&D, Bristol Myers Squibb Parameters of Performance - Driving Drug Delivery Value and Valuation * Josef Bossart, Ph.D., Principal, B4Bio * Guy Furness, Managing Director, ONdrugDelivery Ltd * Brian S. Gorin, Managing Principal, Analysis Group Inc. * Deborah Neveille, Director, Business Analysis, Elan Pharmaceuticals * Ken Andrews, Alkermes * Franck Ziser, VP New Product and Technology Development, Worldwide Product Planning Group, Cephalon * Christopher Searcy, PharmD., MBA, Vice President Corporate Development, Nektar Therapeutics
Developing Products: How Do Emerging Drug Delivery Companies Support The Cost?
* John M. Siebert, Chairman and CEO, CyDex, Inc. * Todd C. Davis, Partner, Paul Capital Partners * Ed Saltzman, President, Defined Health * Chris Seiter, Managing Director, Head of Specialty Pharmaceuticals, Bank of America * Andrew Forman, Senior Analyst and Managing Director, WR Hambrecht + Co * Jack Khattar, President & CEO, Supernus Pharmaceuticals, Inc. Specialty Pharma Pipeline - Build or Buy? * Debra Bingham, Partner, Valeo Partners * Mary Furlong, Executive Vice President, Corporate Development, Lupin Ltd * Tim Howard, Partner, Stonecroft Capital LLC * Ravi Kiron, Ph.D., MBA, Executive Director, New Technology Assessment and Planning, Alza Corporation (a division of Johnson & Johnson) * Christine Mayer, Vice President, Business Development, Biovail Pharmaceuticals
To request the agenda, additional information or to register for the exhibition contact Mark Alexay, the organizer and Executive Vice President, Life Sciences of Strategic Research Institute at malexay@srinstitute.com or 212.967.0095, extension 251. The early registration discount expires on July 21. The conference website is http://www.srinstitute.com/cs375.
Strategic Research Institute
CONTACT: Mark Alexay, the Organizer and Executive Vice President, LifeSciences of Strategic Research Institute, +1-212-967-0095, ext. 251, ormalexay@srinstitute.com
